Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine for the Treatment of Focal Dystonia
NCT00001784Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 1998
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mexiletine in focal dystonia, benign essential blepharospasm (BEB) and writer's cramp (FHD) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Clinical Rating Scales for Dystonia at 13 weeks. Started Jul 1998; status: completed.
02
Drugs
mexiletine
03
Conditions
focal dystoniabenign essential blepharospasm (BEB)writer's cramp (FHD)
Beyond the preview
Go deeper on NCT00001784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001784.